Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.
Identifieur interne : 002593 ( PubMed/Checkpoint ); précédent : 002592; suivant : 002594Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.
Auteurs : Alan Yan [États-Unis] ; Tomer Avraham ; Jamie C. Zampell ; Yosef S. Haviv ; Evan Weitman ; Babak J. MehraraSource :
- Future oncology (London, England) [ 1744-8301 ] ; 2011.
Descripteurs français
- KwdFr :
- Adipocytes (cytologie), Animaux, Cellules HEK293, Cellules cultivées, Cellules souches (), Cellules souches (métabolisme), Facteur de croissance endothéliale vasculaire de type C (pharmacologie), Facteur de croissance transformant bêta-1 (antagonistes et inhibiteurs), Femelle, Glycoprotéines membranaires (métabolisme), Gènes rapporteurs (génétique), Humains, Lymphangiogenèse (), Lymphangiogenèse (physiologie), Prolifération cellulaire (), Souris, Souris de lignée C57BL, Souris transgéniques, Transduction du signal ().
- MESH :
- antagonistes et inhibiteurs : Facteur de croissance transformant bêta-1.
- cytologie : Adipocytes.
- génétique : Gènes rapporteurs.
- métabolisme : Cellules souches, Glycoprotéines membranaires.
- pharmacologie : Facteur de croissance endothéliale vasculaire de type C.
- physiologie : Lymphangiogenèse.
- Animaux, Cellules HEK293, Cellules cultivées, Cellules souches, Femelle, Humains, Lymphangiogenèse, Prolifération cellulaire, Souris, Souris de lignée C57BL, Souris transgéniques, Transduction du signal.
English descriptors
- KwdEn :
- Adipocytes (cytology), Animals, Cell Proliferation (drug effects), Cells, Cultured, Female, Genes, Reporter (genetics), HEK293 Cells, Humans, Lymphangiogenesis (drug effects), Lymphangiogenesis (physiology), Membrane Glycoproteins (metabolism), Mice, Mice, Inbred C57BL, Mice, Transgenic, Signal Transduction (drug effects), Stem Cells (drug effects), Stem Cells (metabolism), Transforming Growth Factor beta1 (antagonists & inhibitors), Vascular Endothelial Growth Factor C (pharmacology).
- MESH :
- chemical , antagonists & inhibitors : Transforming Growth Factor beta1.
- chemical , metabolism : Membrane Glycoproteins.
- cytology : Adipocytes.
- drug effects : Cell Proliferation, Lymphangiogenesis, Signal Transduction, Stem Cells.
- genetics : Genes, Reporter.
- metabolism : Stem Cells.
- chemical , pharmacology : Vascular Endothelial Growth Factor C.
- physiology : Lymphangiogenesis.
- Animals, Cells, Cultured, Female, HEK293 Cells, Humans, Mice, Mice, Inbred C57BL, Mice, Transgenic.
Abstract
Recent studies have demonstrated that augmentation of lymphangiogenesis and tissue engineering hold promise as a treatment for lymphedema. The purpose of this study was to determine whether adipose-derived stem cells (ASCs) can be used in lymphatic tissue-engineering by altering the balance between pro- and anti-lymphangiogenic cytokines.
DOI: 10.2217/fon.11.121
PubMed: 22112321
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22112321Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.</title><author><name sortKey="Yan, Alan" sort="Yan, Alan" uniqKey="Yan A" first="Alan" last="Yan">Alan Yan</name><affiliation wicri:level="2"><nlm:affiliation>The Division of Plastic & Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Division of Plastic & Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Avraham, Tomer" sort="Avraham, Tomer" uniqKey="Avraham T" first="Tomer" last="Avraham">Tomer Avraham</name></author><author><name sortKey="Zampell, Jamie C" sort="Zampell, Jamie C" uniqKey="Zampell J" first="Jamie C" last="Zampell">Jamie C. Zampell</name></author><author><name sortKey="Haviv, Yosef S" sort="Haviv, Yosef S" uniqKey="Haviv Y" first="Yosef S" last="Haviv">Yosef S. Haviv</name></author><author><name sortKey="Weitman, Evan" sort="Weitman, Evan" uniqKey="Weitman E" first="Evan" last="Weitman">Evan Weitman</name></author><author><name sortKey="Mehrara, Babak J" sort="Mehrara, Babak J" uniqKey="Mehrara B" first="Babak J" last="Mehrara">Babak J. Mehrara</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22112321</idno><idno type="pmid">22112321</idno><idno type="doi">10.2217/fon.11.121</idno><idno type="wicri:Area/PubMed/Corpus">002373</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002373</idno><idno type="wicri:Area/PubMed/Curation">002373</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002373</idno><idno type="wicri:Area/PubMed/Checkpoint">002373</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002373</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.</title><author><name sortKey="Yan, Alan" sort="Yan, Alan" uniqKey="Yan A" first="Alan" last="Yan">Alan Yan</name><affiliation wicri:level="2"><nlm:affiliation>The Division of Plastic & Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Division of Plastic & Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Avraham, Tomer" sort="Avraham, Tomer" uniqKey="Avraham T" first="Tomer" last="Avraham">Tomer Avraham</name></author><author><name sortKey="Zampell, Jamie C" sort="Zampell, Jamie C" uniqKey="Zampell J" first="Jamie C" last="Zampell">Jamie C. Zampell</name></author><author><name sortKey="Haviv, Yosef S" sort="Haviv, Yosef S" uniqKey="Haviv Y" first="Yosef S" last="Haviv">Yosef S. Haviv</name></author><author><name sortKey="Weitman, Evan" sort="Weitman, Evan" uniqKey="Weitman E" first="Evan" last="Weitman">Evan Weitman</name></author><author><name sortKey="Mehrara, Babak J" sort="Mehrara, Babak J" uniqKey="Mehrara B" first="Babak J" last="Mehrara">Babak J. Mehrara</name></author></analytic><series><title level="j">Future oncology (London, England)</title><idno type="eISSN">1744-8301</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adipocytes (cytology)</term><term>Animals</term><term>Cell Proliferation (drug effects)</term><term>Cells, Cultured</term><term>Female</term><term>Genes, Reporter (genetics)</term><term>HEK293 Cells</term><term>Humans</term><term>Lymphangiogenesis (drug effects)</term><term>Lymphangiogenesis (physiology)</term><term>Membrane Glycoproteins (metabolism)</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Transgenic</term><term>Signal Transduction (drug effects)</term><term>Stem Cells (drug effects)</term><term>Stem Cells (metabolism)</term><term>Transforming Growth Factor beta1 (antagonists & inhibitors)</term><term>Vascular Endothelial Growth Factor C (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adipocytes (cytologie)</term><term>Animaux</term><term>Cellules HEK293</term><term>Cellules cultivées</term><term>Cellules souches ()</term><term>Cellules souches (métabolisme)</term><term>Facteur de croissance endothéliale vasculaire de type C (pharmacologie)</term><term>Facteur de croissance transformant bêta-1 (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Gènes rapporteurs (génétique)</term><term>Humains</term><term>Lymphangiogenèse ()</term><term>Lymphangiogenèse (physiologie)</term><term>Prolifération cellulaire ()</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris transgéniques</term><term>Transduction du signal ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Transforming Growth Factor beta1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance transformant bêta-1</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Adipocytes</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Adipocytes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Proliferation</term><term>Lymphangiogenesis</term><term>Signal Transduction</term><term>Stem Cells</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Genes, Reporter</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Gènes rapporteurs</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Stem Cells</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cellules souches</term><term>Glycoprotéines membranaires</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type C</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Lymphangiogenèse</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Lymphangiogenesis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Female</term><term>HEK293 Cells</term><term>Humans</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Transgenic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules HEK293</term><term>Cellules cultivées</term><term>Cellules souches</term><term>Femelle</term><term>Humains</term><term>Lymphangiogenèse</term><term>Prolifération cellulaire</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris transgéniques</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent studies have demonstrated that augmentation of lymphangiogenesis and tissue engineering hold promise as a treatment for lymphedema. The purpose of this study was to determine whether adipose-derived stem cells (ASCs) can be used in lymphatic tissue-engineering by altering the balance between pro- and anti-lymphangiogenic cytokines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22112321</PMID><DateCreated><Year>2011</Year><Month>11</Month><Day>24</Day></DateCreated><DateCompleted><Year>2012</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8301</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Future oncology (London, England)</Title><ISOAbbreviation>Future Oncol</ISOAbbreviation></Journal><ArticleTitle>Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.</ArticleTitle><Pagination><MedlinePgn>1457-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/fon.11.121</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Recent studies have demonstrated that augmentation of lymphangiogenesis and tissue engineering hold promise as a treatment for lymphedema. The purpose of this study was to determine whether adipose-derived stem cells (ASCs) can be used in lymphatic tissue-engineering by altering the balance between pro- and anti-lymphangiogenic cytokines.</AbstractText><AbstractText Label="MATERIALS & METHODS" NlmCategory="METHODS">ASCs were harvested and cultured in media with or without recombinant VEGF-C for 48 h. ASCs were then implanted in mice using Matrigel plugs. Additional groups of animals were implanted with ASCs transfected with a dominant-negative TGF-β1 receptor-II adenovirus with or without VEGF-C stimulation, since TGF-β1 has been shown to have potent antilymphangiogenic effects. Lymphangiogenesis, lymphatic differentiation and cellular proliferation were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Stimulation of ASCs with VEGF-C in vitro significantly increased expression of VEGF-A, VEGF-C and Prox-1. ASCs stimulated with VEGF-C prior to implantation induced a significant (threefold increase) lymphangiogenic response as compared with control groups (unstimulated ASCs or empty Matrigel plugs; p < 0.01). This effect was significantly potentiated when TGF-β1 signaling was inhibited using the dominant-negative TGF-β1 receptor-II virus (4.5-fold increase; p < 0.01). Stimulation of ASCs with VEGF-C resulted in a marked increase in the number of donor ASCs (twofold; p < 0.01) and increased the number of proliferating cells (sevenfold; p < 0.01) surrounding the Matrigel. ASCs stimulated with VEGF-C expressed podoplanin, a lymphangiogenic cell marker, whereas unstimulated cells did not.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Short-term stimulation of ASCs with VEGF-C results in increased expression of VEGF-A, VEGF-C and Prox-1 in vitro and is associated with a marked increase lymphangiogenic response after in vivo implantation. This lymphangiogenic response is significantly potentiated by blocking TGF-β1 function. Furthermore, stimulation of ASCs with VEGF-C markedly increases cellular proliferation and cellular survival after in vivo implantation and stimulated cells express podoplanin, a lymphangiogenic cell marker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Division of Plastic & Reconstructive Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avraham</LastName><ForeName>Tomer</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zampell</LastName><ForeName>Jamie C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Haviv</LastName><ForeName>Yosef S</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Weitman</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mehrara</LastName><ForeName>Babak J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 CA009501</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009501-23</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009501-24</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009501-25</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Future Oncol</MedlineTA><NlmUniqueID>101256629</NlmUniqueID><ISSNLinking>1479-6694</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490441">Gp38 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042582">Vascular Endothelial Growth Factor C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Bone Miner Res. 1999 Aug;14(8):1290-301</RefSource><PMID Version="1">10457261</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2009 Jan 20;119(2):281-9</RefSource><PMID Version="1">19118255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2005 Jun 10;96(11):1193-9</RefSource><PMID Version="1">15890974</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Microvasc Res. 2006 Nov;72(3):161-71</RefSource><PMID Version="1">16876204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Pharm Bull. 2007 Apr;30(4):633-7</RefSource><PMID Version="1">17409493</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Tissue Eng. 2007 Jun;13(6):1299-312</RefSource><PMID Version="1">17518741</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2009 Mar 15;69(6):2669-76</RefSource><PMID Version="1">19276384</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Tissue Eng Part A. 2009 Jul;15(7):1833-41</RefSource><PMID Version="1">19125645</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2009 Aug;124(2):438-50</RefSource><PMID Version="1">19644258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Tissue Eng Part A. 2010 Feb;16(2):653-62</RefSource><PMID Version="1">19754224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2010 Oct 5;122(14):1413-25</RefSource><PMID Version="1">20855662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Nov 15;116(22):5138-49</RefSource><PMID Version="1">20665892</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Stem Cell. 2010 Dec 3;7(6):718-29</RefSource><PMID Version="1">21112566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2010 Dec;177(6):3202-14</RefSource><PMID Version="1">21056998</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2010 Dec;24(12):4877-88</RefSource><PMID Version="1">20720160</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2011 Feb 15;123(6):613-20</RefSource><PMID Version="1">21282502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(2):e17201</RefSource><PMID Version="1">21359148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Nucl Med. 2011 Apr;36(4):277-82</RefSource><PMID Version="1">21368600</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2011 Jul;32(19):4415-23</RefSource><PMID Version="1">21421266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2010;12(5):R70</RefSource><PMID Version="1">20825671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Oncol. 2009 Mar;34(3):673-80</RefSource><PMID Version="1">19212672</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2001 Mar 1;61(5):1786-90</RefSource><PMID Version="1">11280723</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2001 Sep 15;92(6):1368-77</RefSource><PMID Version="1">11745212</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gene Med. 2003 Oct;5(10):839-51</RefSource><PMID Version="1">14533192</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2004 Jun 25;279(26):27088-97</RefSource><PMID Version="1">15102829</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2004 Aug 1;22(15):3070-9</RefSource><PMID Version="1">15284257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stem Cells. 2007 Oct;25(10):2648-59</RefSource><PMID Version="1">17615264</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cell Physiol. 2008 Feb;214(2):413-21</RefSource><PMID Version="1">17654479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2007 Dec;13(12):1458-66</RefSource><PMID Version="1">18059280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2008 Feb 15;180(4):2581-7</RefSource><PMID Version="1">18250469</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Transplant. 2007;16(9):963-70</RefSource><PMID Version="1">18293895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2008 Apr;121(4):1144-52</RefSource><PMID Version="1">18349631</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 May 1;111(9):4571-9</RefSource><PMID Version="1">18310502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jul 20;26(21):3536-42</RefSource><PMID Version="1">18640935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Aug 15;112(4):1129-38</RefSource><PMID Version="1">18541717</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2008 Sep;122(3):739-48</RefSource><PMID Version="1">18766036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2008 Nov 14;376(2):419-22</RefSource><PMID Version="1">18789891</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Nov 10;26(32):5213-9</RefSource><PMID Version="1">18838709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2113-27</RefSource><PMID Version="1">18849330</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Dec 10;26(35):5689-96</RefSource><PMID Version="1">19001331</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Biol Med (Maywood). 2009 Jan;234(1):1-9</RefSource><PMID Version="1">19109553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2005 Jul 1;332(2):370-9</RefSource><PMID Version="1">15896706</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017667" MajorTopicYN="N">Adipocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042583" MajorTopicYN="N">Lymphangiogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042582" MajorTopicYN="N">Vascular Endothelial Growth Factor C</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS347916</OtherID><OtherID Source="NLM">PMC3263831</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22112321</ArticleId><ArticleId IdType="doi">10.2217/fon.11.121</ArticleId><ArticleId IdType="pmc">PMC3263831</ArticleId><ArticleId IdType="mid">NIHMS347916</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Avraham, Tomer" sort="Avraham, Tomer" uniqKey="Avraham T" first="Tomer" last="Avraham">Tomer Avraham</name><name sortKey="Haviv, Yosef S" sort="Haviv, Yosef S" uniqKey="Haviv Y" first="Yosef S" last="Haviv">Yosef S. Haviv</name><name sortKey="Mehrara, Babak J" sort="Mehrara, Babak J" uniqKey="Mehrara B" first="Babak J" last="Mehrara">Babak J. Mehrara</name><name sortKey="Weitman, Evan" sort="Weitman, Evan" uniqKey="Weitman E" first="Evan" last="Weitman">Evan Weitman</name><name sortKey="Zampell, Jamie C" sort="Zampell, Jamie C" uniqKey="Zampell J" first="Jamie C" last="Zampell">Jamie C. Zampell</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Yan, Alan" sort="Yan, Alan" uniqKey="Yan A" first="Alan" last="Yan">Alan Yan</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002593 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002593 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22112321
|texte= Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22112321" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |